Cyprotex is the world's largest contract research organisation specialising in preclinical ADME Tox. Our acquisition of Apredica in 2010 enables us to provide the most complete range of ADME Tox CRO services available:
- High Throughput ADME screening
- Customised ADME assays
- NEW! gADME™ technology
- In silico ADME predictive modeling
- In vitro toxicology
Integrated drug discovery services (medicinal chemistry, synthetic chemistry, computational chemistry and biology) are now available through our strategic alliance with Sygnature Discovery.
Find out more about us.
Get more information on our extensive range of ADME and toxicology services.
Call us on:
+44 1625 505 100 (UK)
+1 617 923 6400 (US)
This website was last updated
on 27th January 2012
on 27th January 2012
This website is intended to assist investors, industry participants, customers
and employees to understand Cyprotex’s global operations and ambitions.
Certain information and detail is disclosed in the interest of compliance
of AIM Rule 26.